s6y Co-Diagnostics, Inc. 8-K

Co-Diagnostics, Inc. 8-K, filed Nov 20, 2026: Current report filing

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2026

 

CO-DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

 

Utah 001-38148 46-2609363

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices) (Zip Code)

 

(801) 438-1036

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   CODX   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Funding of Additional Loan

 

On November 18, 2026, Co-Diagnostics, Inc. (the “Company”) borrowed the additional loan contemplated by the Loan Agreement, dated as of October 9, 2026 (the “Loan Agreement”), between the Company and J.J. Astor & Co. (the “Lender”) as disclosed in the Company’s Current Report on Form 8-K filed on October 13, 2026. The Lender funded $1.0 million (the “Additional Loan”), and the Company issued to the Lender a senior secured convertible installment promissory note having an original principal amount of $1.35 million (the “Additional Note”). The original principal amount of the Additional Note reflects a factor rate of 1.35 times the funded amount. The Lender retained a $40,000 origination fee, resulting in net cash proceeds to the Company of $960,000 before other transaction expenses. The Company intends to use the net proceeds for general working capital purposes.

 

The Additional Note has an original issue date of November 18, 2026, requires 30 weekly installment payments of $45,000 beginning November 25, 2026, and has a final maturity date of June 16, 2027. The Additional Note is secured by a senior-priority lien on substantially all assets of the Company and its existing subsidiaries as subsidiary guarantors pursuant to that certain Pledge and Security Agreement, dated October 9, 2026 and the Subsidiary Guarantee dated October 9, 2026.

 

The Company may prepay the Additional Note at any time without penalty. If the Additional Note is paid in full within 45 days after its funding date and no event of default has occurred, the repayment amount will be reduced to reflect a factor rate of 1.29 times the applicable funded amount, less all weekly installment payments previously made. Upon an event of default, the outstanding balance becomes immediately due and payable, the outstanding principal amount of all notes issued under the Loan Agreement is increased to 120% of the then-outstanding principal amounts, bear default interest at 19% per annum, compounded daily (the “Default Amount”) and may be converted by the Lender at the event of default Conversion Price (as defined in the Loan Agreement).

 

The Lender may convert all or any portion of the payment amount under the Additional Note into shares of the Company’s common stock (the “Conversion Shares”) at a conversion price equal to the greater of (i) 90% of the lowest volume-weighted average price of the common stock during the 10 consecutive trading days immediately preceding the conversion date and (ii) the minimum price determined under applicable Nasdaq listing rules, subject to a floor price equal to 20% of the Nasdaq minimum price and other customary adjustments. On the six-month anniversary of the execution of the Loan Agreement, and every six months thereafter, the floor price will be reset to the lower of (i) the floor price then in effect or (ii) 20% of the lowest volume weighted average price of the Company’s common stock during the twenty trading days preceding such reset; provided that the floor price will not be reduced below 20% of the Nasdaq minimum price unless and until the Company obtains stockholder approval.

 

In connection with the funding, the Company and the Lender agreed to waive certain conditions under the Loan Agreement that otherwise would have required the Additional Loan to be requested and funded no earlier than December 8, 2026 and on at least five business days’ notice. The parties also waived the conditions that the closing price of the Company’s common stock on the trading day immediately preceding the funding date be at least $1.00 per share and that the Company’s previously approved reverse stock split has become effective before the funding date. The Company is required to cause the reverse stock split to become effective on or before November 24, 2026, and failure to do so constitutes an event of default under the Additional Note. The waiver does not waive any other condition to funding the Additional Loan.

 

The foregoing description of the Additional Note does not purport to be complete and is qualified in its entirety by reference to the full text of the Additional Note, which is filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

2
 

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

 

The Company issued the Additional Note in reliance on the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof and/or Rule 506(b) of Regulation D promulgated thereunder. The Lender represented that it is an “accredited investor” as defined in Rule 501(a) of Regulation D. Neither the Additional Note nor any shares of common stock issuable upon conversion of the Additional Note have been registered under the Securities Act. Any such shares issued absent registration may not be offered or sold in the United States absent registration or an applicable exemption from registration.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
4.1   Senior Secured Convertible Note issued to J.J. Astor & Co., dated November 18, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

3
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.
Dated: November 20, 2026    
  By: /s/ Dwight H. Egan
  Name: Dwight H. Egan
  Title: Chief Executive Officer

 

4